# Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

> **NCT00372619** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 74 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** clofarabine
- **DRUG:** cytarabine
- **DRUG:** methotrexate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00372619
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372619, "Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00372619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*